Illumina (NASDAQ:ILMN) Stock Rating Lowered by Barclays

Barclays cut shares of Illumina (NASDAQ:ILMNFree Report) from an equal weight rating to an underweight rating in a research note published on Monday, MarketBeat.com reports. Barclays currently has $100.00 price objective on the life sciences company’s stock, down from their previous price objective of $130.00.

A number of other brokerages also recently issued reports on ILMN. Leerink Partners raised their price objective on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. raised their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a research report on Thursday, October 17th. Finally, TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and dropped their target price for the company from $177.00 to $140.00 in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Illumina has an average rating of “Moderate Buy” and a consensus price target of $159.45.

View Our Latest Stock Analysis on Illumina

Illumina Trading Up 2.9 %

Shares of NASDAQ ILMN opened at $103.57 on Monday. The firm has a 50 day moving average price of $135.10 and a two-hundred day moving average price of $135.34. The stock has a market cap of $16.43 billion, a P/E ratio of -13.49 and a beta of 1.10. Illumina has a 52-week low of $99.35 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMNGet Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. As a group, equities analysts forecast that Illumina will post 4.42 EPS for the current year.

Hedge Funds Weigh In On Illumina

A number of institutional investors have recently modified their holdings of the company. Norges Bank acquired a new stake in Illumina in the 4th quarter valued at $228,714,000. WCM Investment Management LLC grew its holdings in shares of Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after buying an additional 867,673 shares during the last quarter. Pictet Asset Management Holding SA increased its position in shares of Illumina by 245.7% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,182,454 shares of the life sciences company’s stock worth $158,011,000 after acquiring an additional 840,423 shares in the last quarter. ARK Investment Management LLC acquired a new stake in shares of Illumina in the 4th quarter worth about $91,714,000. Finally, Massachusetts Financial Services Co. MA lifted its position in Illumina by 148.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after acquiring an additional 631,294 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Company Profile

(Get Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Featured Articles

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.